Mark Shearman Resigns as Chief Scientific Officer of Applied Genetic Technologies Corporation

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is on the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM) and a optogenetics program, as well as a preclinical program in dry age-related macular degeneration (dAMD). It has approximately one preclinical program in otology and two preclinical programs targeting central nervous system disorders (CN), including frontotemporal dementia and amyotrophic lateral sclerosis. Its optogenetics program is being developed in collaboration with Bionic Sight, LLC and its otology program is being developed in collaboration with Otonomy, Inc. In addition to its product pipeline, the Company has also developed broad technological and manufacturing capabilities in synthetic promoter development and optimization.